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Abstract
Background. The PRE-dialysis survey on anaemia
management (PRESAM) was designed to assess the
care given to pre-dialysis patients in the 12 months
before haemodialysis or peritoneal dialysis, with emphasis
on anaemia management.
Methods. For this epidemiological study, a retro-
spective chart review was conducted for patients who
started haemodialysis or peritoneal dialysis between
1 August, 1999 and 6 April, 2000. All adult patients
who entered one of the 779 participating centres in
21 European countries, Israel or South Africa were
included, except for patients who underwent dialysis
only during an acute episode. In addition to demo-
graphic characteristics, the study examined the pre-
valence of anaemia, anaemia management including
the use of iron supplementation and epoetin, source of
referral to the dialysis centre, comorbidities and major
clinical events.
Results. A total of 4333 new dialysis patients were
included in the survey. At the first visit to the dialysis
centre, 68% of the patients had a haemoglobin (Hb)
concentration O11.0 gudl; Hb concentration was posi-
tively correlated with creatinine clearance rate (rs
0.43, P-0.01). Patients who received epoetin had
a mean Hb concentration of 8.8 gudl at the start of
epoetin treatment, and 96% of these patients had
an Hb concentration O11.0 gudl. Only 26.5% of the
patients received epoetin before dialysis. The length of
time under the care of a nephrologist was associated
with meeting the European Best Practice Guidelines
(EBPG) target Hb concentration, as well as receiving
epoetin.
Conclusions. Few pre-dialysis patients met the EBPG
target for Hb concentration, despite regular nephrology
care.
Keywords: anaemia management; best practice guide-
lines; epidemiology; epoetin; pre-dialysis
Introduction
The treatment of patients with chronic renal failure
with recombinant human erythropoietin (rHuEPOu
epoetin) before starting or during dialysis can improve
the patient’s functional state, quality of life and
probably the risk of morbidity and death [1–3]. In
1997, the National Kidney Foundation published
the Dialysis Outcomes Quality Initiative Clinical
Practice Guidelines for the Treatment of Anaemia
of Chronic Renal Failure [4]. These evidence-based
guidelines provide criteria on how to make best use of
diagnostic and therapeutic procedures for the treat-
ment of patients with anaemia before starting and
during dialysis treatment.
In 1999, the European Dialysis and Transplanta-
tion Association (EDTA) published the European Best
Practice Guidelines (EBPG) for the treatment of renal
patients with anaemia [5]. These guidelines reviewed
200 additional publications and, based on three levels
of evidence in accordance with the criteria of the US
Agency for Health Care Policy and Research, updated
the recommendations for the diagnosis and treatment
of patients with anaemia from a European point of
view. The EBPG aim to achieve haemoglobin (Hb)
concentrations )11.0 gudl in 85% of renal patients.
The European Survey on Anaemia Management
(ESAM) [6] was published in 2000. This survey com-
piled prospective epidemiological data relating to the
treatment of anaemia in a selected group of patients
(ns14 527) on haemodialysis or peritoneal dialysis
from 14 European countries. The results of this survey
emphasized the small percentage of patients who began
epoetin treatment pre-dialysis (only 11% of the patients
on haemodialysis), and the low Hb concentration in
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patients at the start (mean -9.0 gudl) and at the end
of treatment.
The PRE-dialysis Survey on Anaemia Manage-
ment (PRESAM) has been designed with the aim of
evaluating the nephrological and anaemia manage-
ment of pre-dialysis patients during the 12 months
before dialysis. In this survey, the participating centres
were asked to include all patients who started dialysis
between 1 August, 1999 and 6 April, 2000. Retrospec-
tive data on the patients, and the diagnosis and treat-
ment of anaemia were requested for the 12 months
pre-dialysis. This survey fulfilled two objectives: to
reveal the diagnostic and therapeutic patterns of
anaemia in these patients and to document the pattern
of referral of patients with chronic renal disease to a
nephrologist before the start of dialysis in Europe,
Israel and South Africa. A detailed analysis of the
patient referral pattern will be presented elsewhere [7].
Subjects and methods
Study design
The PRESAM used a retrospective chart review to evaluate
the management of anaemia in patients with chronic renal
failure during the year before the start of dialysis. The
inclusion criteria specified the enrolment of all patients aged
16–99 years who started haemodialysis or peritoneal dialysis
in a participating dialysis centre between 1 August, 1999 and
6 April, 2000. Selection bias was prevented by the inclusion
of all dialysis patients, except those patients who started
dialysis for acute reasons and did not remain on dialysis
after the acute episode. This epidemiological observational
survey did not require any deviation from routine medical
practice. Therefore, Institutional Review Board approval
was either waived or expedited in participating institutions
and informed consent was not required. The survey included
patients from 779 dialysis centres from 21 European
countries, as well as Israel and South Africa (Table 1). All
physicians at dialysis centres in these countries were invited
to participate in the survey. Participation was on a voluntary
basis, without restrictions.
Data collection and management
Collected data included: start date of dialysis, date of the
first visit to a nephrologist, aetiology of chronic renal
failure, source of referral to dialysis centre, date of the first
consultation in the dialysis centre where the patient is
currently dialysed, clinical data on the first visit to dialysis
centre (including body weight, blood pressure, Hb and serum
creatinine concentrations), and data related to comorbidity
(such as diabetes type 1 or 2, hypertension, haemoglobino-
pathy, coronary heart disease, neoplasia, chronic hepatitis,
cardiac failure, bronchopneumopathy, infectious disease, arrhy-
thmia and inflammatory disease). Data were also collected
on drug treatments, iron supplementation, major clinical
events in the year as well as the month before dialysis
(including angina pectoris, cardiac failure, myocardial
infarction, infectious disease, inflammatory disease, bleeding,
transfusion, surgery other than dialysis access and renal
transplantation), and the type of vascular access (native
fistula, synthetic fistula or catheter) when starting haemo-
dialysis. Finally, the use of epoetin (including the physician
who started epoetin treatment, epoetin dose, route and
frequency of administration, and reasons for starting
epoetin treatment), iron supplementation, Hb concentra-
tion, serum ferritin and serum creatinine concentrations,
and transferrin saturation at the start of epoetin treat-
ment were documented. Reasons for starting epoetin
treatment could be low Hb concentration, cardiac failure,
coronary heart disease, symptoms of anaemia (i.e. tiredness
and dyspnoea), patient complaint or other. In addition,
the target Hb concentration (the concentration aimed for
in the individual patient, which was decided at the start
of epoetin treatment and at the start of dialysis) was
recorded [8].
Data were collected using a three-page pre-printed data
collection tool (DCT). Each participating centre received
DCTs and detailed instructions for their completion. The
DCTs were scanned electronically using TELEform1 scan-
ning software. The scanned DCTs were reviewed and
validated, and added to an SPSS1 database. Data were
then edited against a previously established series of domain
and consistency edits. These established criteria-specified
mandatory fields including the year of birth, start date of
dialysis and serum creatinine concentration at the first visit
to the dialysis centre. Of the 4729 original DCTs, 396 (8%)
lacked data in one or more of these outlined areas and were
therefore excluded from the database. The resulting analy-
tical database therefore consisted of 4333 valid cases for
which the mandatory data were available. Some of the non-
mandatory data, however, were not available for all 4333
cases because of values outside the predefined boundaries,
Table 1. Sample size by country and region
Western Europe Sample
size
Number of
participating centres
Austria 182 31
Belgium 158 13
Denmark 70 8
Finland 58 4
France 432 156
Greece 129 42
Italy 360 80
Netherlands 146 13
Portugal 202 28
Spain 639 24
Switzerland 80 28
UK 425 38
Subtotal 2881 465
Central and eastern Europe
Bulgaria 43 5
Croatia 85 20
Czech Republic 212 61
Hungary 271 39
Lithuania 32 10
Poland 438 95
Russia 89 12
Slovakia 142 29
Slovenia 32 10
Subtotal 1344 281
Other countries
Israel 74 16
South Africa 34 17
Subtotal 108 33
Total 4333 779
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logical inconsistencies with other data, or questionable or
missing units.
Data transformations included the calculation of creat-
inine clearance using the Cockcroft–Gault formula as
follows:
for men: ([140 – age] 3 weight in kg)u(72 3 serum creatinine
in mgudl);
for women: {0.85 3 ([140 – age] 3 weight in kg)}u(72 3 serum
creatinine in mgudl) [9].
Iron status was also calculated using the following criteria:
adequate iron statussserum ferritin P100 mgul q transferrin
saturation P20%; functional iron deficiencysserum ferritin
100 mgul q transferrin saturation -20%; absolute iron
deficiencysserum ferritin -100 mgul.
Statistical analysis
Standard descriptive statistics were calculated for all study
variables. Bivariate and multivariate distributions were
examined by plotting distributions and stratification. Differ-
ence testing between groups was performed using the two-
tailed t-test, analysis of variance, x2 or their non-parametric
equivalent where appropriate. Significance for main effects
was tested at the as0.05 level.
Results
Epidemiology
The sample consisted of 4333 patients who had
recently started dialysis (Table 2). Data for several
variables were not recorded for all these patients. Fifty-
nine percent of patients were male (total ns4265). The
mean age of all enrolled patients at the start of dialysis
was 59.1"15.6 years, with a median age of 62 years
(total ns4333). Approximately 16% of the patients
started dialysis at age 75 years or older.
The two most common aetiologies of renal failure
in the survey sample were diabetic nephropathy (23%)
and chronic glomerulonephritis (19%) (total ns4289).
Vascular nephropathy (including hypertensive nephro-
sclerosis) and tubulo-interstitial nephropathy occurred
in 10–13% of the patients.
Four of the five most prevalent comorbidities at a
patient’s first visit to a dialysis centre were cardiac-
related: hypertension (78%), coronary heart disease
(23%), cardiac failure (15%) and arrhythmia (8%).
Eighty-four percent of patients had at least one cardio-
vascular comorbidity, including hypertension (total
ns4333). Excluding hypertension, 34% of the patients
had at least one of the following conditions: coronary
heart disease, cardiac failure or arrhythmia. Diabetic
patients comprised 30.8% (1336u4333) of the total
survey sample and they had a significantly higher rate
of hypertension compared with non-diabetic patients
(ns2997) (84 versus 76%, P-0.01). Similarly, 36%
of the diabetic patients had coronary heart disease
and 22% had cardiac failure compared with 18 and
12%, respectively, of non-diabetic patients (P-0.01).
At their first visit to the dialysis centre, 57.3% of the
patients (total ns3918) had been under the care of a
nephrologist for )1 year, 31.4% had been under the
Table 2. Demographic and clinical data
Variable na Percentb Mean SD Median
Gender 4265
Male 2511 58.9
Female 1754 41.1
Type of dialysis 4190
Haemodialysis 3659 87.3
Peritoneal dialysis 531 12.7
Type of vascular access 3582
Native fistula 1976 55.2
Synthetic fistula 82 2.3
Catheter 1524 42.5
Age at first visit to a nephrologist (years) 4267 55.7 17.2 59.0
Parameters at first visit to dialysis centre
Age (years) 4317 57.3 16.2 60.0
Hb concentration (gudl) 4020 10.0 2.1 9.9
Serum creatinine concentration (mmolul) 4333 528.2 289.5 495.0
Creatinine clearance rate (mlumin) 3903 18.2 16.7 12.3
Length of time under care of nephrologist (months) 3918
O1 554 14.1
1–6 679 17.3
6–12 439 11.2
)12 2246 57.3
Parameters at start of dialysis
Age (years) 4333 59.1 15.6 62.0
Hb concentration (gudl) 3629 9.5 1.7 9.4
Serum creatinine concentration (mmolul) 3611 720.2 221.2 702.0
Creatinine clearance rate (mlumin) 3276 9.8 3.9 9.1
Iron supplementation 4187 42.4
aNumber of patients from the total population of 4333 for whom data were available.
bCalculated from the patients for whom data were available.
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care of a nephrologist for -6 months and 14.1% for
-1 month (Table 2). Haemodialysis was started for
87.3% of the patients, whereas peritoneal dialysis was
started for 12.7% (total ns4190). For more than half
of the sample, dialysis was started because of fluid
overload. Other reasons included severe acidosis and
malnutrition. At the start of dialysis, 42.4% of the
patients received iron supplementation (total ns4187).
Table 3. Anaemia status: comparison between western Europe (WE) and centralueastern Europe (CEE) countries
Variable na Percentb Mean SD Median Pc
All patients WE 2881
CEE 1334
Targetd Hb (gudl) at start of dialysis WE 2117 11.7 0.7 12.0 -0.01
CEE 743 11.3 0.8 11.0
Hb (gudl) at start of dialysis WE 2437 9.8 1.6 9.8 -0.01
CEE 1105 8.7 1.8 8.6
Hb (gudl) at start of epoetin WE 2104 9.0 1.2 9.0 -0.01
CEE 747 8.2 1.3 8.3
Iron supplementation WE 2758e 42 -0.01
CEE 1323e 39
Iron status at start of dialysis
Adequate iron stores WE 534 36 -0.01
CEE 234 53
Functional iron deficiency WE 333 22
CEE 81 18
Absolute iron deficiency WE 636 42
CEE 126 29
aNumber of patients, from total population of 4333, for whom data were available.
bPercent of patients from the number for whom data were available.
ct-test and Pearson’s x2 were used where appropriate.
dIndividually set target Hb.
eSample size reflects all patients who responded yesuno to iron supplementation, while the percentage reflects those patients that responded yes.
Table 4. Epoetin treatment and anaemia status in the entire survey sample
Variable na Percentb Mean SD Median
All patients (ns4333)
Targetc Hb (gudl) at start of dialysis 2943 11.6 0.7 12.0
Hb (gudl) at start of dialysis 3629 9.5 1.7 9.4
Hb (gudl) at start of epoetin 2910 8.8 1.3 8.8
Iron supplementation 4187 42
Iron status at start of dialysis:
Adequate iron stores 794 40
Functional iron deficiency 432 22
Absolute iron deficiency 771 39
Cohort: epoetin started before dialysis (ns1085)
Targetc Hb (gudl) at start of dialysis 977 11.7 0.7 12.0
Hb (gudl) at start of dialysis 1041 10.3 1.7 10.2
Hb (gudl) at start of epoetin 1043 9.0 1.1 9.0
Iron supplementation 1060 67
Cohort: epoetin and dialysis started simultaneously (ns1332)
Targetc Hb (gudl) at start of dialysis 1088 11.5 0.8 12.0
Hb (gudl) at start of dialysis 1187 8.9 1.5 8.8
Hb (gudl) at start of epoetin 1254 8.6 1.3 8.6
Iron supplementation 1276 40
Cohort: epoetin started after dialysis (ns523)
Targetc Hb (gudl) at start of dialysis 308 11.5 0.7 11.5
Hb (gudl) at start of dialysis 410 9.2 1.7 9.1
Hb (gudl) at start of epoetin 489 8.7 1.3 8.7
Iron supplementation 506 32
Cohort: no epoetin (ns1155)
Targetd Hb (gudl) at start of dialysis 437 11.5 0.8 11.5
Hb (gudl) at start of dialysis 842 9.4 1.8 9.5
Iron supplementation 1121 25
aNumber of patients, from total population of 4333, for whom data were available.
bPercent of patients from the number for whom data were available.
cIndividually set target Hb concentration.
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Haemoglobin values
At the patients’ first visit to the dialysis centre, the
mean Hb concentration was 10.0"2.1 gudl (total
ns4020) (Table 2), and 68% of the patients had an
Hb concentration O11.0 gudl. The mean Hb concen-
tration at the start of dialysis was 9.5"1.7 gudl,
and 80% of the patients had an Hb concentration
O11.0 gudl (total ns3629). There was a significant
difference in the mean Hb concentration between
patients from western Europe (9.8"1.6 gudl) and those
from central or eastern Europe (8.7"1.8 gudl) (P-0.01)
(Table 3). For patients who received epoetin, the mean
Hb concentration at the start of epoetin was 8.8 gudl,
and 96% of these patients had Hb concentrations
O11.0 gudl (ns2910) (Table 4). The mean Hb con-
centration was 9.0"1.2 gudl for patients from western
Europe and 8.2"1.3 gudl for patients from central or
eastern Europe (P-0.01) (Table 3).
The mean Hb concentration at the start of dialysis
increased slightly but significantly with the length of
time a patient had been under the care of the nephro-
logist (P-0.01) (Figure 1). The mean Hb concentra-
tion for patients under the care of a nephrologist for
-1 month was 8.9 gudl, for 1–6 months it was 9.5 gudl,
and for 6–12 months as well as for )1 year it was
9.6 gudl (total ns3306). The same trend was observed
when patient samples from western Europe or from
central and eastern Europe were analysed separately
(Figure 1B).
Fig. 1. Haemoglobin (Hb) concentration at start of dialysis by length of time under care of nephrologist. (A) Global analysis of all patients.
Mean Hb concentration at start of dialysis significantly increased with length of time under care of a nephrologist (P-0.01, ANOVA).
(B) Separate analysis of patients from western Europe and of patients from central and eastern Europe.
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The Hb concentration at the first visit to the dialysis
centre was positively correlated with creatinine clear-
ance rate (rs0.43; P-0.01), but there was consider-
able variability. For example, at a creatinine clearance
rate of 20 mlumin, the Hb concentration ranged from
4.8 to 14.2 gudl. At the first visit to the dialysis centre,
patients with creatinine clearance rates )50 mlumin
had a mean Hb concentration of 12.0 gudl, those with
rates of 40–50 mlumin had a mean Hb concentration
of 12.3 gudl, those with rates of 30–40 mlumin had a
mean Hb concentration of 11.7 gudl, those between
20 and 30 mlumin had a mean Hb concentration of
11.0 gudl, those 10–20 mlumin had 9.8 gudl, and those
with a creatinine clearance of -10 mlumin had a mean
Hb concentration of 9.0 gudl. The association between
Hb concentration and creatinine clearance rate was
similar for diabetic and non-diabetic patients who
were not treated with epoetin (ns1777) (Figure 2).
The percentage of patients with a Hb concentration
below the EBPG target of )11.0 gudl was progres-
sively smaller with improving creatinine clearance
rates (Figure 3). Conversely, the percentage of patients
maintaining an Hb concentration between 11.0 and
13.0 gudl (Figure 3) increased with improving creati-
nine clearance rates. For both epoetin- and non-
epoetin-treated patients, the mean creatinine clearance
rates were low (12.4 and 12.0 mlumin, respectively)
for those who had an Hb concentration -9.0 gudl
at the first visit to the dialysis centre. Creatinine
clearance rate progressively increased with increasing
Fig. 3. Percentage of patients with haemoglobin (Hb) concentrationO11.0 gudl or between 11.0 and 13.0 gudl by creatinine clearance rate at
first visit to dialysis centre. In diabetic as well as in non-diabetic patients, the percentage of patients with Hb concentrations O11.0 gudl was
progressively smaller with improving estimated creatinine clearance rates.
Fig. 2. Haemoglobin (Hb) concentration by creatinine clearance at first visit to dialysis centre, in patients with and without diabetes mellitus.
There was a significant correlation between Hb concentration and estimated creatinine clearance (rs0.43; P-0.01; ns1777). For any
estimated creatinine clearance, diabetic patients were not more severely anaemic than non-diabetic patients.
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Hb concentration, to a high mean of 33.0 mlumin
(epoetin-treated) and 29.3 mlumin (non-epoetin-treated)
in those with an Hb concentration P12.0 gudl.
Epoetin treatment
Only 26.5% (1085u4095) of the patients started epoetin
treatment before dialysis (Table 4). Dialysis was started
before epoetin treatment in 12.8% (523u4095) of the
patients, epoetin and dialysis were started simulta-
neously in 32.5% (1332u4095) of the patients, and
28.2% (1155u4095) did not receive epoetin at any time.
The mean Hb concentration at the start of dialysis
in patients who had received epoetin before starting
dialysis was 10.3 gudl compared with 9.2 gudl in those
who started epoetin after dialysis, 8.9 gudl in those
who started epoetin and dialysis simultaneously, and
Fig. 4. Start of epoetin treatment in relation to dialysis by length of time under care of nephrologist. (A) Global analysis of all patients. The
percentage of patients starting epoetin treatment before dialysis increased with length of time under care of a nephrologist. (B) Separate
analysis of patients from western Europe and of patients from eastern Europe. In both cases, the percentage of patients starting epoetin
treatment before dialysis increased with length of time under care of a nephrologist, but this percentage was lower for patients from central
and eastern Europe than for patients from western Europe.
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9.4 gudl in those who received no epoetin (Table 4).
The percentage of patients meeting the EBPG target
Hb concentration of )11.0 gudl at the start of dialysis
was 31% of those who started epoetin first, 14% of
those who started dialysis first, 8% of those who
started dialysis and epoetin simultaneously, and 17%
of those who were not treated with epoetin.
The percentage of patients who received epoetin
before dialysis increased with the length of time under
the care of a nephrologist (Figure 4A and B). There
was also an increase in the mean Hb concentration at
the start of epoetin treatment for patients who received
epoetin before dialysis, from 8.5 gudl in patients who
were under the care of a nephrologist for -1 month
(ns18) to 9.1 gudl in patients under the care of a
nephrologist for )1 year (ns711). When patients
from western Europe were analysed separately, the
mean Hb concentration increased from 8.6 gudl in
patients who were under the care of a nephrologist
for -1 month (ns17) to 9.1 gudl for those who were
under the care of a nephrologist for )12 months
(ns606) (Figure 4B). In the entire sample, patients
who started epoetin pre-dialysis had a mean Hb
concentration of 9.0 gudl at the start of epoetin
treatment (ns994). Those who started dialysis first
had a mean Hb concentration of 8.7 gudl at the start
of epoetin treatment (ns444) and those who started
epoetin and dialysis simultaneously had a mean Hb
concentration of 8.6 gudl (ns1112) (Figure 4A). For
patients from western Europe, mean Hb concentra-
tions at the start of epoetin were 9.2 gudl (ns212) for
those who started dialysis first and 8.8 gudl (ns773)
for those who started epoetin and dialysis simulta-
neously (Figure 4B). For patients from central and
eastern Europe, these Hb concentrations were 8.3 gudl
(ns228) and 8.1 gudl (ns329), respectively (Figure 4B).
Clinicians were more likely to start epoetin treat-
ment if patients had both a low Hb concentration and
symptoms of anaemia (tiredness, dyspnoea) (41%, total
ns3013). Hb concentration alone was the reason
for starting treatment in 25% of the patients (total
ns3018).
The mean dose at the start of epoetin treatment
was 6302"3944 IUuweek. For patients who received
epoetin pre-dialysis (ns1031), the mean dose was
5832"3429 IUuweek. This was similar to the mean
dose for patients who received epoetin after the start
of dialysis (5660"3542 IUuweek) (ns488). These mean
doses were significantly lower than those for patients in
whom dialysis and epoetin were started simultaneously
(6852"4208 IUuweek; Fs28.9, P-0.01) (ns1244).
The association between Hb concentration and epoetin
dose was weak for all patients regardless of when
epoetin was started in relation to dialysis.
Iron supplementation
At the start of dialysis, 40% had adequate iron status
and 60% had iron deficiency (39% had absolute defi-
ciency and 22% functional deficiency) (total ns1997).
Two-thirds of the patients who received epoetin
pre-dialysis also received iron supplementation (total
ns1060) (Table 4). Of the patients who started epoe-
tin and dialysis simultaneously (ns1276), only 40%
received iron supplementation, although 59% were
iron deficient. In the patients who started epoetin
treatment after dialysis (ns506), 32% received iron
supplementation, although 62% were iron-deficient.
In the patients treated with epoetin, there were no
significant differences in iron status (i.e. adequate,
functional deficiency, or absolute deficiency) between
those who started epoetin before, after or simulta-
neously with dialysis. Of the patients who were not
treated with epoetin, 56% were iron-deficient (37%
absolutely and 19% functionally).
No iron supplementation was given to 74.6% of the
patients who did not receive epoetin, whereas only
51.0% of the patients who were treated with epoetin
were not supplemented. Additionally, of the patients
who were treated with epoetin pre-dialysis, only 33%
did not receive iron supplementation. Of the patients
who received epoetin pre-dialysis and also iron
supplementation, the majority (67%) were treated
with oral iron only, 16% were treated with intravenous
(i.v.) iron only and 10% were given both i.v. and oral
therapy.
Patients without iron supplementation received the
highest mean epoetin dose of 6591 IUuweek (ns4187).
Patients with both i.v. and oral iron supplementa-
tion received a mean epoetin dose of 5940 IUuweek,
those with only oral iron received a mean dose of
5861 IUuweek, and those given i.v. iron alone were
treated with the lowest epoetin dose with a mean of
5278 IUuweek.
Attainment of EBPG targets
The EBPG for the management of anaemia in
renal patients recommends an individual target Hb
concentration of )11.0 gudl, and aims for an Hb
concentration of )11.0 gudl in 85% of all patients.
The mean individual target Hb concentration in the
overall PRESAM sample at the start of dialysis was
11.6"0.7 gudl (total ns2943) (Table 4). Nevertheless,
only 18% of the patients had an actual Hb concentra-
tion )11.0 gudl at the start of dialysis (Figure 5A).
This percentage was 22% for patients from western
Europe, and 10% for patients from eastern or central
Europe (Figure 5B). Overall, the lowest incidence of
Fig. 5. EBPG on anaemia management: attainment of Hb and ferritin targets at start of dialysis by length of time under care of nephrologist.
(A) Global analysis of all patients. (B) Analysis of the percentage of patients reaching Hb concentrations )11.0 gudl at start of dialysis by
length of time under care of a nephrologist, according to the country of origin (western Europe vs central and eastern Europe). (C) Analysis of
the percentage of patients reaching ferritin concentrations P100 mgul at start of dialysis by length of time under care of a nephrologist,
according to the country of origin (western Europe vs central and eastern Europe).
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patients who met the EBPG target Hb concentration
of )11.0 gudl was in the cohort who had been under
the care of a nephrologist for -1 month (ns455)
(Figure 5A). This was also observed when patients
from western Europe or from eastern and central
Europe were analysed separately (Figure 5B). In the
cohort who had been under the care of a nephrologist
for )12 months, both EBPG targets for Hb and
ferritin concentrations were met by 26% of all patients
in the sample who received both epoetin and iron,
compared with only 18% of the patients who received
epoetin only, 11% who received iron only, or 11% who
received neither treatment. A comparison of patients
from western Europe and from central and eastern
Europe showed that a greater proportion of patients
from western Europe were iron-deficient (P-0.01)
(Figure 5C).
Comorbidity
Patients treated with epoetin pre-dialysis had signifi-
cantly lower rates of cardiac failure in the year before
dialysis than patients not treated with epoetin pre-
dialysis (20 vs 24%, P-0.05). They also had signi-
ficantly lower incidences of ischaemic heart disease
(either angina or myocardial infarction) (17 vs 21%,
P-0.05) and lower rates of blood transfusion (17 vs
21%, P-0.05). Furthermore, 11% required blood trans-
fusions in the month before dialysis, compared with
19% of those who did not receive epoetin pre-dialysis
(P-0.001). Similarly, patients treated with epoetin
pre-dialysis also had lower rates of clinical events in
the month before dialysis compared with those who
did not receive epoetin pre-dialysis (cardiac failure 20
vs 23%, P-0.05; ischaemic heart disease 12 vs 16%,
P-0.001).
Discussion
The PRESAM survey provided an opportunity to
study a sample of 4333 incident patients in various
countries. The epidemiological value of this sample
is that all patients starting dialysis at any of the
participating centres have been included. The mean
age at the start of dialysis was 59.1 years (median
62 years), which is negligibly lower than in the ESAM
[6] (mean 61 years and median 64 years). This is
because the study population in the ESAM consisted
of prevalent patients, whereas in the PRESAM it
consisted of incident patients. In this survey, we found
that the most common cause of chronic renal failure
was diabetic nephropathy (23%), followed by chronic
glomerulonephritis (19%) and vascular nephropathy,
including hypertensive nephropathy (13%). In the
ESAM [6], the second most common prevalent disease
was diabetic nephropathy (18%). In the USA, analysis
of data from the United States Renal Data System
(USRDS) showed that diabetic nephropathy was also
by far the most frequent cause of end-stage renal
failure, followed by hypertensive nephropathy and
chronic glomerulonephritis [10]. In addition to the
advanced age of patients and frequency of diabetes,
there were also frequent, significant comorbidities
documented during the first visit to a dialysis centre.
Hypertension, coronary heart disease, heart failure and
arrhythmia were frequently recorded during the first
visit and diabetic patients showed these comorbidities
more often than non-diabetic patients.
The finding that 57% of the patients who were
referred to a dialysis centre had been under the care of a
nephrologist for )1 year and only 14% for -1 month
is promising. The latter are patients who, according
to several authors [11,12], would have to be considered
as being so-called ‘late referrals’. However, the
mean creatinine clearance rate at the first visit to a
nephrologist was only 18.2 mlumin, with over 35% of
the patients having rates below 10 mlumin. Therefore,
despite more than half of the patients being under
the care of a nephrologist for )1 year, most arrived at
the dialysis centre with an extremely advanced degree
of renal insufficiency.
It is of particular significance that in this survey
68% of the patients had an Hb concentrationO11.0 gudl
(mean Hb concentration, 10.0 gudl) when they arrived
at the dialysis centre for the first time, and should
therefore, according to the EBPG, be considered for
treatment with epoetin. Even when only patients from
western Europe were considered, 78% had an Hb
concentration O11.0 gudl (median Hb concentration,
9.8 gudl). The mean Hb concentration at the start of
the treatment with epoetin was only 8.8 gudl. These
values are very similar to those observed in the ESAM
survey, despite the fact that the ESAM patients were
on dialysis and had started treatment several years
before. The patients who had been under the care
of a nephrologist for )1 year had higher Hb concen-
trations than those who had been referred later.
Nevertheless, these patients started haemodialysis
with a mean Hb concentration of 9.6 gudl, which is
still much lower than the recommended concentration.
Even when only patients from western Europe were
considered, this latter group of patients started dialysis
with a mean Hb concentration of 9.8 gudl. In other
words, as in the ESAM survey, the inadequate treat-
ment of patients with anaemia cannot be attributed
exclusively to the late referral of the patients. It may
also be attributed to the fact that some nephrologists
do not follow the recommendations in the EBPG.
Comparisons between patients from western and from
easternucentral Europe show that patients from east-
ernucentral Europe are less likely to receive epoetin
treatment before starting dialysis, and have lower Hb
concentrations at the start of epoetin treatment as
well as at the start of dialysis. This probably reflects
differences in funding available to the health care
systems in the respective regions.
For patients who were not treated with epoetin and
who had not received blood transfusions in previous
months, there was a clear correlation between the
degree of renal insufficiency (creatinine clearance
rate) and the degree of anaemia (Hb concentration).
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However, there was great variability, and patients with
creatinine clearance rates as low as 20 mlumin had a
range of Hb concentrations from severe anaemia to
normal (from 4.8 to 14.2 gudl). In patients with
creatinine clearance rates )50 mlumin, the mean Hb
concentration was only 12.0 gudl, indicating that there
was a large proportion of anaemic patients in this
group. Another notable finding is that no significant
differences were observed in the relationship between
Hb concentration and creatinine clearance rate in
diabetic patients compared with non-diabetic patients.
This is in contrast to other studies, which showed that
diabetic patients are more affected by anaemia with
declining renal function [13].
In this survey we observed that 26.5% of all patients
in the sample received treatment with epoetin before
starting dialysis (36% of the patients from western
Europe and 10% of the patients from central or eastern
Europe). In a review of more than 150 000 patients
on dialysis in the USA, Obrador et al. [14] found that
only 23% of the sample had received treatment with
epoetin before starting dialysis. It is also of interest to
emphasize that in our survey patients who start dialysis
when they already receive epoetin have a higher Hb
concentration than those not being treated (10.3 versus
9.2 gudl), though the concentration is still much lower
than that recommended in the EBPG. In addition, the
mean Hb concentration was 9.2 gudl in patients who
started treatment with epoetin after dialysis. This study
showed that the patients who had been under the care
of a nephrologist for )1 year have received treatment
with epoetin more often. When the reasons for starting
treatment with epoetin were analysed, Hb concentra-
tion alone was only responsible for 25% of the cases.
It appears that doctors postponed treatment with
epoetin until patients showed symptoms of anaemia. The
mean initial dose was slightly )6000 IUuweek (but this
varied greatly), and the mean dose was lower in patients
who were treated with epoetin before dialysis.
A total of 60% of the patients were iron-deficient
(39% absolutely and 22% functionally), and two-thirds
of the patients treated with epoetin pre-dialysis also
received iron supplementation. The iron status of the
patients did not improve with length of time under the
care of a nephrologist. Iron supplementation conti-
nued to be insufficient, perhaps because only 26% of
the patients received i.v. iron supplementation, and some
nephrologists probably do not follow the recommen-
dations in the EBPG. As observed in the ESAM, in
patients who did not receive iron supplementation,
doses of epoetin were the highest.
The EBPG recommend an individual target Hb
concentration of )11.0 gudl with the aim of achieving
this in 85% of the patients in the unit. For the patients
studied in the PRESAM, however, the mean individual
target was 11.6 gudl (median value: 12.0 gudl for patients
in western Europe and 11.0 gudl for patients in central or
eastern Europe), but only 18% of the patients (22% of the
patients from western Europe and 10% of the patients
from central or eastern Europe) had an Hb concentration
)11.0 gudl when starting dialysis. The percentage of
patients whose Hb concentration reached 11.0 gudl
was correlated with the length of time under the care
of a nephrologist. One significant observation was
that a lower incidence of heart failure and ischaemic
heart disease is observed in the patients undergoing
treatment with epoetin before dialysis than in patients
who were not treated with epoetin before the start
of dialysis. The cohort treated with epoetin before
dialysis also had significantly lower rates of blood
transfusions than those not treated with epoetin.
In summary, this pre-dialysis survey serves to draw
attention to the following points. More than 30% of
the patients had been followed by a nephrologist for
-6 months when they started dialysis, which probably
invalidated or reduced the effectiveness of measures
taken to delay the progression of chronic renal in-
sufficiency and control comorbidity. Cardiovascular
comorbidities are extremely common, particularly in
diabetic patients and, in this survey, diabetes was the
most common cause of chronic renal insufficiency.
Although being under the care of a nephrologist for
)1 year is associated with less frequent (predomi-
nantly heart-related) complications, only a small
proportion of patients receive treatment with epoetin
before starting dialysis. Patients start dialysis with
severe anaemia, and treatment with epoetin is started
at Hb concentrations far below those recommended
by the EBPG.
It is to be hoped that the data reported in this survey
may draw attention to the risks of late treatment of
anaemia and help to improve the management of
anaemia during the initial stages of chronic renal
insufficiency. Such improvements in practice may
positively impact quality of life and cardiac status,
and may even delay the progression of chronic renal
insufficiency [15].
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